Key facts
| Price (PPV) | 158.20 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbersatanhydrochlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | POLYMEDIC |
| Presentation | Boite de 30 |
| Nature | Médicament |
| Hospital price | 98.90 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l’hypertension artérielle essentielle. Cette association à dose fixe est indiquée chez les patients adultes dont la pression artérielle est insuffisamment contrôlée par l’irbésartan seul ou l’hydrochlorothiazide seul.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Co-Arapro 300 mg / 12.5 mg (ZENITH PHARMA) contains the same active substance as Coavacor 300 mg / 12.5 mg (Irbersatan | Hydrochlorothiazide) at the same strength, but in a different pack: Boite de 10 at 60.70 MAD, i.e. 6.07 MAD per unit against 5.27 MAD for Coavacor 300 mg / 12.5 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Novortan Plus 300 mg / 12.5 mg | NOVOPHARMA | Boite de 30 | 158.20 MAD | 5.27 / unit | — |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 30 | 160.90 MAD | 5.36 / unit | — |
| Co-Arapro 300 mg / 12.5 mg | ZENITH PHARMA | Boite de 30 | 169.30 MAD | 5.64 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Arapro 300 mg / 12.5 mg | ZENITH PHARMA | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Co-Icard 300 mg / 12.5 mg | COOPER PHARMA | Boite de 14 | 85 MAD | 6.07 / unit |
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 14 | 85 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 20 | 88.50 MAD | 4.43 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Coavacor 300 mg / 12.5 mg
Coavacor 300 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by POLYMEDIC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Coavacor 300 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Coavacor 300 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.